CD274 and esophageal squamous cell carcinoma: Four phase III randomized controlled trials (RCTs) compared anti-PD-1 therapy with second-line systemic chemotherapy in patients with advanced ESCC who previously failed platinum-based chemotherapy and had not had prior anti-PD-1/PD-L1 therapy.